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Activation of the c-Jun NH2-terminal kinase (JNK) signaling
pathway is involved in the immune response; however, little
is known of its role in immune-induced renal injury. In this
study, we examine JNK signaling in the rat anti-glomerular
basement membrane (GBM) disease model using CC-401, a
specific JNK inhibitor. Animals were given CC-401, vehicle
alone or no treatment starting before anti-GBM serum
injection and continued treatment until killing. In acute
disease, CC-401 blocked JNK signaling and reduced
proteinuria in the first 24 h. The transient neutrophil influx
seen at 3 h of disease was not affected, however. Continued
CC-401 treatment suppressed glomerular and
tubulointerstitial damage usually seen at 14 days.
The protective effect may be due to modulation of
macrophage activation, as CC-401 had no effect upon
glomerular macrophage infiltration at day 14 despite the
suppression of glomerular lesions and a marked reduction in
renal tumor necrosis factor-a and inducible nitric oxide
synthase messenger RNA levels. Treatment with CC-401 had
no apparent effect on T cell or humoral immune responses.
These studies suggest that JNK signaling promotes renal
injury in acute and progressive rat anti-GBM disease.
JNK inhibitors may be a novel therapeutic approach for
the treatment of human glomerulonephritis.
Kidney International (2007) 72, 698–708; doi:10.1038/sj.ki.5002404;
published online 27 June 2007
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The c-Jun amino-terminal kinase (JNK) pathway is activated
by a wide variety of immunological and stress stimuli,
including: pro-inflammatory cytokines (tumor necrosis
factor-a (TNF-a), interleukin-1), Toll-like receptor signaling
by exogenous and endogenous ligands (endotoxin and heat-
shock proteins), growth factors (angiotensin II, transforming
growth factor-b1), oxidative stress, and osmotic shock.1
These stimuli induce a cascade of kinase phosphorylation
events, leading to the dual phosphorylation of the Thr-X-Tyr
activation motif of JNK. The active (phosphorylated) form of
JNK can then phosphorylate-specific target proteins, mostly
transcription factors, to modulate gene transcription result-
ing in a variety of cellular responses, including: production of
pro-inflammatory molecules; modulation of cell differentia-
tion, proliferation, and apoptosis.1 A feature of JNK is that it
is the only known kinase that phosphorylates Ser63 and Ser73
in the NH2-terminal activation domain of c-Jun.
2–5 Thus,
detection of c-Jun phosphorylation at these residues can be
used as a read-out of JNK activity. Indeed, c-Jun is an
important target of JNK signaling, as, when phosphorylated,
it can combine with c-fos to form the transcription factor,
AP-1, which promotes transcription of pro-inflammatory
molecules such as interleukin-1b, monocyte chemoattractant
protein-1 (MCP-1), and intercellular adhesion molecule-1.6
There are three genes encoding closely related JNK
enzymes, termed JNK1–3.1 Although Jnk1 (Mapk8) and
Jnk2 (Mapk9) are widely expressed in most cell types,
including the kidney, Jnk3 (Mapk10) is restricted to the
nervous system, heart, and testes. Furthermore, alternative
RNA splicing results in the production of up to 10 different
JNK isoforms of approximately 46 and 54 kDa.7 The wide-
spread expression of both Jnk1 and Jnk2 can make it difficult
to define functional roles for this pathway due to redundancy
in signaling, and the finding that combined genetic deficiency
for Jnk1 and Jnk2 is fetal lethal.
JNK signaling plays a role in the immune response.
Specific functions for Jnk1 and Jnk2 have been described in
the differentiation of naı¨ve T cells into T-helper type 1
effector cells,8–10 although the role of JNK signaling in the
secondary immune response has not been investigated.
In addition, in vitro studies have shown that endotoxin-
induced nitric oxide production and that Fcg-receptor
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activation induced TNF-a production by macrophages is
dependent upon JNK signaling.11,12 Furthermore, adminis-
tration of a JNK inhibitor drug has been shown to inhibit
joint inflammation and erosion in rat adjuvant-induced
arthritis.13
Activation of JNK signaling has been identified in a
number of experimental models of immune-mediated kidney
disease including rat anti-glomerular basement membrane
(GBM) glomerulonephritis and passive Heymann’s nephri-
tis,14–16 as well as in models of renal injury induced by non-
immune insults.17–19 It is known that macrophages are
critical effector cells in causing both acute and progressive
renal injury in experimental models of anti-GBM disease.20,21
Furthermore, modulation of macrophage activation can have
a substantial impact upon renal injury.22,23
We previously investigated the role of JNK signaling in an
adoptive transfer model in which ex vivo JNK inhibition was
shown to suppress macrophage-induced acute renal injury.24
However, it remains to be determined whether: (i) JNK
signaling is important in progressive immune-mediated renal
injury and (ii) JNK blockade modulates the individual
components of the renal immune response.
The primary aim of this study was to determine whether
therapeutic targeting of JNK signaling, via systemic admin-
istration of a JNK inhibitor, can suppress acute and
progressive glomerular and tubulointerstitial damage in
immune-mediated kidney disease. The secondary aim of this
study was to determine whether systemic inhibition of JNK
signaling modulates the various components of the renal
immune response in terms of neutrophils, macrophages,
T cells, and the humoral response. To achieve these aims, we
used a specific JNK inhibitor, CC-401, to treat a rat model of
anti-GBM glomerulonephritis.
RESULTS
JNK activation in normal kidney and in acute anti-GBM
disease
In normal rat kidney, Western blotting shows a weak signal
for phosphorylated JNK (p-JNK) in glomeruli (Figure 1a),
whereas immunostaining localizes p-JNK to parietal epithe-
lial cells of Bowman’s capsule (Figure 2a) and occasional
podocyte-like cells within the glomerular tuft. A marked
increase in JNK phosphorylation is evident on day 1 of anti-
GBM disease (Figure 1a), with many p-JNKþ cells seen
within the glomerular tuft (Figure 2d). Direct evidence of
JNK signaling can be derived from phosphorylation of c-Jun
at Ser63, a specific JNK target. c-Jun is not expressed in
normal rat kidney, except for occasional parietal epithelial
cells, but c-Jun is rapidly induced in anti-GBM disease
(Figure 2). Western blotting demonstrates phosphorylation
of c-Jun at Ser63 in glomeruli on day 1 of anti-GBM disease
(Figure 1a), while immunostaining identifies glomerular cells
positive for p-c-Jun Ser63 immunostaining (Figure 2f).
Double immunostaining identified p-c-Jun Ser63 staining
in many ED1þmacrophages and in some cells of a podocyte
morphology (Figure 3).
CC-401 inhibits JNK activation in acute anti-GBM disease
CC-401 is a specific inhibitor of the JNK signaling pathway,
which has been described in detail.19,25 CC-401 inhibits JNK
signaling by competitive binding to the adenosine triphos-
phate-binding site in the active, phosphorylated, form of
JNK, resulting in inhibition of the phosphorylation of JNK
targets, such as the amino-terminal activation domain of the
transcription factor, c-Jun. Two initial experiments were
performed in which CC-401 was administered to rats at 100
or 200 mg/kg bid, beginning 2 h before injection of anti-GBM
serum with animals killed at 24 h. Western blot analysis
(performed only in the 200 mg/kg dose experiment) showed
that CC-401 treatment virtually abrogated phosphorylation
of c-Jun at Ser63 (Figure 1a and b). In contrast, CC-401 had
no effect upon phosphorylation of JNK (Figure 1a and c), as
expected. CC-401 had no effect upon phosphorylation of the
closely related kinases, p38 and ERK (Figure 1), indicating
that the drug did not affect the activity of any up-stream
kinases in these pathways. Immunostaining was performed in
both experimental groups and the results are shown in
Figure 2. Consistent with Western blotting analysis, treatment
of anti-GBM disease with 100 mg/kg CC-401 abrogated the
presence of glomerular immunostaining for p-c-Jun Ser63,
although glomerular cells stained for p-JNK were still evident
(Figure 2).
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Figure 1 | CC-401 inhibits JNK signaling in acute anti-GBM
disease. (a) Western blotting of isolated glomeruli from normal rats,
or day 1 anti-GBM disease with no treatment (No Tx), vehicle
treatment (Veh) or 200 mg/kg CC-401 treatment (CC-401) was
performed for p-c-Jun Ser63, p-JNK, p-p38, p-ERK, and tubulin.
(b–e) Graphs showing quantification of the different phosphorylated
proteins compared with the tubulin control.
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CC-401 inhibits renal injury in acute anti-GBM disease
This disease model features moderate to heavy proteinuria
within 24 h of injection of anti-GBM serum. In separate
experiments, both doses of CC-401 treatment resulted in
substantial protection from proteinuria (Figure 4a and b).
Administration of 100 mg/kg CC-401 produced peak blood
drug levels of 1.8770.69 mM. This was in the target range of
1–3 mM peak drug blood levels and this dose was effective in
suppressing JNK signaling. Therefore, all subsequent studies
and analysis used CC-401 treatment at a dose of 100 mg/kg.
Induction of anti-GBM disease at 24 h was associated with
glomerular infiltration of ED1þmacrophages and R73þT
cells, and upregulation of renal gene expression for the
pro-inflammatory molecules; TNF-a, inducible nitric oxide
synthase (iNOS), and MCP-1 (Figure 5a–e). CC-401 treat-
ment resulted in a partial reduction in glomerular macro-
phage accumulation, but had no effect upon glomerular
T-cell infiltration (Figure 5a and b). The increase in renal
TNF-a and MCP-1 gene expression in anti-GBM disease was
prevented by CC-401 treatment, whereas the increase in
iNOS messenger RNA (mRNA) levels – which are very low in
normal kidney – were only partially suppressed by CC-401
treatment (Figure 5).
JNK blockade does not affect glomerular neutrophil influx in
acute anti-GBM disease
Both neutrophils and macrophages contribute to the
induction of proteinuria during the first 24 h in this model
of anti-GBM disease.20,26 Glomerular neutrophil influx peaks
at 3 h after anti-GBM serum injection and is largely resolved
by 24 h. Therefore, we performed a separate experiment to
examine the effect of JNK blockade on neutrophil recruit-
ment. A prominent neutrophil influx was evident 3 h after
anti-GBM serum injection in untreated animals versus
normal controls (Figure 6a and b). In addition, glomerular
cells positive for p-c-Jun Ser63 were seen at 3 h (Figure 6e),
although this was substantially less than the number of
infiltrating neutrophils. Treatment with CC-401 had no effect
upon glomerular neutrophil accumulation (Figure 6). The
efficacy of CC-401 treatment was confirmed by the abolition
of glomerular staining for p-c-Jun Ser63 (Figure 6f), and
achieving serum CC-401 levels of 1.7870.72 mM.
JNK blockade prevents progressive renal injury in rat anti-
GBM disease
To determine whether the beneficial effects of CC-401
treatment could be sustained beyond the initial injury, we
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Figure 2 | Immunostaining of JNK signaling in acute anti-GBM disease. (a) Immunostaining for p-JNK is seen in parietal cells of
Bowman’s capsule in normal rats (arrows). (b) No glomerular staining is apparent in normal kidney for c-Jun (c) or p-c-Jun Ser63.
Day 1-untreated anti-GBM disease shows a marked increase in glomerular staining for: (d) p-JNK, (e) c-Jun, and (f) p-c-Jun Ser63. CC-401
treatment of anti-GBM disease did not prevent the induction of (g) JNK phosphorylation, (h) or c-Jun expression in glomerular cells, but CC-401
prevented (i) c-Jun phosphorylation at Ser63. (a–f) Original magnification,  400.
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performed a study in which 100 mg/kg bid CC-401 treatment
was begun 2 h before injection of anti-GBM serum injection
and continued until animals were killed 14 days later.
Untreated and vehicle-treated anti-GBM disease exhibited
heavy proteinuria during the first 24 h of disease and this was
sustained for the 14-day period, leading to a marked
reduction in serum albumin levels (Figure 7a and b).
Untreated and vehicle-treated anti-GBM disease exhibited
significant glomerular damage on day 14 of anti-GBM disease
with periodic acid-Schiff (PAS) staining showing focal and
segmental adhesions, fibrinoid necrosis, hyalinosis, and
atrophy (Figures 7c and 8a). Secondary to glomerular
damage and proteinuria, patchy areas of focal tubulointer-
stitial damage featuring tubular dilation and atrophy, cast
formation and mononuclear cell infiltration were evident in
most animals (Figures 7d and 8a). The induction of vimentin
expression was used as a marker of tubular damage (Figures
7e and 8c). JNK signaling was prominent in damaged tubules
as determined by immunostaining for p-c-Jun Ser63, with
staining also evident within glomerular and interstitial cells
(Figure 8e). No significant renal failure was evident in this
model.
CC-401 treatment (100 mg/kg bid) caused a 50–70%
reduction in the degree of proteinuria during the first 24 h
following injection of anti-GBM serum (Figure 7a), con-
sistent with the results of the 24 h study. This reduction in
proteinuria was maintained over the 14-day time-course and
partially protected animals from the severe hypoalbuminemia
seen in the untreated and vehicle-treated disease groups
(Figure 7a and b). CC-401-treated rats exhibited only mild
glomerular lesions (Figures 7c and 8b). The secondary
tubulointerstitial lesions were substantially reduced as shown
by PAS staining and a reduction in tubular vimentin
expression (Figures 7 and 8). In addition, CC-401 treatment
inhibited JNK signaling as shown by a dramatic reduction in
p-c-Jun Ser63 immunostaining (Figure 8f).
Effect of JNK blockade upon the immune response in anti-
GBM disease
The development of glomerular and tubulointerstitial lesions
on day 14 of anti-GBM disease in untreated and vehicle-
treated groups was associated with a significant interstitial
Figure 3 | JNK signaling in glomerular macrophages. Two color
immunostaining for p-c-Jun Ser63 (brown nuclei) and
ED1þmacrophages (purple/blue) in a glomerulus on day 1 of
untreated anti-GBM disease. Arrows indicate cells stained for both
ED1 and p-c-Jun Ser63, demonstrating JNK signaling in macrophages.
Arrowhead shows p-c-Jun ser63 immunostaining in a podocyte-like
cell. Original magnification,  400.
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Figure 4 | CC-401 inhibits proteinuria in acute anti-GBM disease.
(a and b) Anti-GBM disease was induced in two separate
experiments, in which rats received CC-401, vehicle (Veh), or no
treatment (No Tx) beginning 2 h before anti-GBM serum
administration and continued until animals were killed on day 1.
CC-401 was administered at (a) 100 mg/kg, or (b) 200 mg/kg.
Graphs show the effect of drug treatment on proteinuria.
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Figure 5 | Effect of CC-401 on leukocyte infiltration and gene
expression in acute anti-GBM disease. Anti-GBM disease was
induced in rats, which were either untreated (No Tx) or treated with
100 mg/kg CC-401. (a) Graph of ED1þmacrophages per glomerular
cross-section (gcs). (b) Graph of R73þ T cells per gcs. Real-time
reverse transcription-polymerase chain reaction was used to quantify
relative kidney mRNA levels of: (c) TNF-a, (d) iNOS, and (e) MCP-1.
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T-cell infiltrate, whereas glomerular T cell numbers were not
different to normal by this time point (Figure 9c and d),
consistent with previous studies in this model.27 CC-401
treatment caused a significant reduction in interstitial T-cell
accumulation (Figure 9d), consistent with the overall
reduction in tubulointerstitial injury seen with drug
treatment. To analyze the effector T-cell response, we
performed a 24 h skin delayed-type hypersensitivity response
to an intradermal challenge with sheep immunoglobulin
(Ig)G. Untreated and vehicle-treated anti-GBM disease
groups had a significant increase in skin thickness in response
to challenge with sheep IgG (1.5770.35 and 1.3870.59 mm,
respectively) and this response was not significantly altered
by CC-401 treatment (1.1770.51 mm; P¼not significant
versus vehicle and no treatment groups).
On day 14 of anti-GBM disease, immunofluorescence
staining identified glomerular deposition of sheep anti-rat
GBM antibodies, rat IgG and C3, and this was not affected by
CC-401 treatment (data not shown). As an additional
assessment of the humoral immune response, we measured
the serum titer of rat IgG antibodies against sheep Ig. The
serum levels of total rat IgG against sheep Ig were
significantly increased in CC-401-treated animals. Further
analysis showed that the serum levels of the IgG1, IgG2a, and
IgG2b subclasses of rat anti-sheep Ig were increased, although
the increase in IgG1 failed to reach significance compared
with the no treatment group (Figure 9e-h). This increase in
serum levels of rat anti-sheep IgG may simply reflect a
reduced level of urinary loss of serum proteins in the CC-
401-treated animals. Data from CC-401, vehicle, and no
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Figure 6 | CC-401 does not affect acute neutrophil influx in
anti-GBM disease. Anti-GBM disease was induced in rats, which were
treated with 100 mg/kg CC-401, or vehicle (Veh), and animals killed
3 h after anti-GBM serum administration. (a) Immunostaining shows a
lack of RP1þ neutrophils in normal glomeruli, (b) a marked
neutrophil infiltrate in anti-GBM disease, which was unaffected by
(c) CC-401 treatment. (d) Immunostaining for p-c-Jun Ser63 shows
a lack of staining in normal glomeruli, (e) the presence of several
positive glomerular cells in anti-GBM disease, which was abolished
with (f) CC-401 treatment. (g) Graph showing quantification of
neutrophils as assessed by area of glomerular RP1 immunostaining.
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Figure 7 | CC-401 suppresses renal injury on day 14 of anti-GBM
disease. Anti-GBM disease was induced in rats, which were given
CC-401, vehicle (Veh), or no treatment (No Tx) throughout the 14 day
study. The effect of CC-401 treatment on progressive anti-GBM
disease was assessed in terms of: (a) proteinuria over the disease
course, Po0.05 versus GBM No Tx and GBM Veh at day 1; (b) serum
albumin levels at day 14; (c) glomerular lesions, (d) tubulointerstitial
damage; and (e) quantification of the percentage of tubules
immunostained for vimentin.
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treatment groups on day 14 of anti-GBM disease (n¼ 34)
were pooled and analyzed using the Pearson single correla-
tion coefficient. A significant negative correlation was seen
between the degree of proteinuria and the serum titer of rat
anti-sheep total IgG and the IgG1, IgG2a, and IgG2b
subclasses (all Po0.05). Similarly, when examining the CC-
401-treated group alone (n¼ 14), a significant negative
correlation was seen between the degree of proteinuria and
the serum titer of rat anti-sheep total IgG and the IgG1 and
IgG2b subclasses (all Po0.05), except for IgG2a (P¼ 0.053).
The prominent glomerular macrophage infiltrate seen on
day 14 of anti-GBM disease was unaltered by CC-401
treatment (Figure 9a), despite a substantial reduction in
glomerular lesions. In contrast, the substantial macrophage
accumulation seen in the tubulointerstitium in vehicle and
untreated anti-GBM disease was prevented by CC-401
treatment (Figure 9b), in line with the reduction in
tubulointerstitial damage.
Consistent with the 24 h study, CC-401 treatment
prevented the increase in renal mRNA levels for TNF-a and
MCP-1, while markedly reducing iNOS mRNA levels (Figure
10). The increase in transforming growth factor-b1 mRNA
levels seen on day 14 of anti-GBM disease was also prevented
by CC-401 treatment (Figure 10d).
DISCUSSION
This study has, for the first time, demonstrated that
therapeutic targeting of the JNK signaling pathway can
suppress both acute and progressive immune-mediated renal
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Figure 8 | Effect of CC-401 on immunopathology on day 14 of
anti-GBM disease. (a) PAS staining of untreated day 14 anti-GBM
disease shows glomerular hyalinosis, focal adhesions, segmental
fibrinoid necrosis, and atrophy. In addition, tubulointerstitial damage
is evident in terms of tubular dilatation and atrophy, protein casts,
and focal and diffuse mononuclear cell infiltration. (b) CC-401-treated
anti-GBM disease shows glomerular hypercellularity with
well-preserved capillary loops and mild tubulointerstitial changes.
(c) Immunostaining shows the induction of vimentin expression by
damaged tubules in an area of focal tubulointerstitial injury in
untreated anti-GBM disease. (d) CC-401 treatment of anti-GBM
disease largely prevented the induction of tubular vimentin
expression, whereas constitutive vimentin staining of glomerular
podocytes and interstitial cells is unaffected. (e) Immunostaining
shows p-c-Jun Ser63 staining of cells in the glomerulus and
Bowman’s capsule, plus strong staining in damaged tubules in an
area of focal tubulointerstitial injury. (f) CC-401 treatment almost
entirely prevented c-Jun phosphorylation at Ser63. (a–f) Original
magnification  250.
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Figure 9 | Effect of CC-401 treatment on the immune response on
day 14 of anti-GBM disease. Anti-GBM disease was induced in rats
that received CC-401, vehicle (Veh), or no treatment (No Tx),
throughout the 14 day study. Quantification of immunostaining for
ED1þmacrophages in (a) glomeruli and (b) the interstitium.
Quantification of R73þ T cells in (c) glomeruli and (d) the interstitium.
Serum levels rat IgG antibodies recognizing the immunizing antigen,
sheep Ig, in terms of: (e) total IgG, (f) IgG1, (g) IgG2a, and (h) IgG2b,
as measured by enzyme-linked immunosorbent assay. *Po0.05
versus no Tx; #Po0.05 versus Veh.
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injury. The effect of JNK inhibition on the individual
components of the immune response is discussed below.
This model of anti-GBM disease features a transient
glomerular neutrophil influx in the first few hours after
administration of anti-GBM serum, which promotes the
acute induction of proteinuria.26 Immunostaining indicated
that few neutrophils show JNK activation. The ability of
CC-401 treatment to suppress acute proteinuria was not due
to a reduction in the transient neutrophil influx seen at the
3 h time point. An effect of CC-401 on neutrophil function
cannot be ruled out, but this appears unlikely based upon
previous studies showing that JunD is the only Jun family
member expressed in neutrophils,28 and that JunD is
considered a negative regulator of c-Jun function.29 However,
even if CC-401 did suppress acute renal injury via an effect
upon neutrophil function, this could not account for the
ongoing suppression of progressive anti-GBM disease seen
with CC-401 treatment, as previous studies have shown that
proteinuria and glomerular lesions develop rapidly in the face
of sustained neutrophil depletion, which abrogates the acute
phase of renal injury.26
Macrophages are critical effector cells in causing both
acute and progressive renal injury in experimental models of
anti-GBM disease.20,21 Modulation of macrophage activation
can have a substantial impact upon renal injury.22,23 We have
previously demonstrated that inhibition of JNK signaling
suppresses macrophage iNOS and TNF-a production
in vitro.24 Furthermore, ex vivo inhibition of JNK signaling
can suppress macrophage-mediated renal injury in an
adoptive transfer model of acute anti-GBM disease.24 This
study supports these findings and provides substantial new
information. First, JNK signaling was shown to be prominent
in glomerular macrophages in anti-GBM disease on the basis
of immunostaining. Second, data in this study suggest that
the main mechanism by which administration of CC-401
treatment suppressed acute and progressive anti-GBM disease
was through inhibition of macrophage activation (see below),
arguing that oral administration of a JNK inhibitor can
effectively target macrophage function. This conclusion is
based upon the marked reduction in iNOS and TNF-a
mRNA levels and the reduction in glomerular lesions seen
with CC-401 treatment, despite the lack of effect upon
glomerular macrophage accumulation.
Previous studies have shown that macrophages are the
major, if not the only, cell type responsible for iNOS
expression in the injured kidney.30–34 Thus, the substantial
reduction in iNOS mRNA levels seen with CC-401 treatment
of anti-GBM disease is evidence that inhibition of JNK
signaling can suppress macrophage activation in vivo.
However, it is not clear whether this reduction in iNOS
mRNA levels contributes to the protection against renal
injury with CC-401 treatment, as the pathogenic role of
iNOS in anti-GBM disease remains controversial.35
It is known that macrophages are a potent source of TNF-a
in the injured kidney, although other intrinsic renal cell
types including podocytes and tubular epithelial cells can also
express TNF-a.36–38 However, leukocyte-depletion studies
have shown that the increase in glomerular TNF-a produc-
tion in anti-GBM disease is macrophage dependent.39 Thus,
the ability of CC-401 treatment to prevent upregulation of
renal TNF-a mRNA levels in anti-GBM disease is another
argument that inhibition of JNK signaling can suppress
macrophage activation in vivo. Furthermore, blocking studies
have demonstrated a pathological role for TNF-a in
promoting renal injury in this model of rat anti-GBM
disease,40 indicating that suppression of renal TNF-a gene
expression is likely to be one mechanism by which CC-401
treatment inhibited renal injury.
The finding that glomerular macrophage numbers at day
14 of anti-GBM disease were unaltered with CC-401
treatment despite a substantial reduction in glomerular
lesions is consistent with blockade of JNK signaling
modifying macrophage function. This result extends previous
findings in which ex vivo JNK blockade did not prevent
glomerular macrophage accumulation, but did reduce acute
macrophage-mediated renal injury.24
JNK blockade did not appear to affect glomerular
endothelial cell activation on the basis that both acute
neutrophil and T-cell influx and the progressive glomerular
macrophage accumulation were unaffected, although this
issue has not been examined in the present study. The
inability of JNK blockade to affect glomerular macrophage
accumulation day 14 of anti-GBM disease despite preventing
upregulation of MCP-1 mRNA levels is consistent with the
development of glomerular macrophage infiltration in anti-
GBM disease in MCP-1 (Ccl2) gene-deficient mice,41
although antibody-based MCP-1 blockade has shown a
partial reduction of glomerular macrophage numbers in
anti-GBM disease.42
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Figure 10 | Effect of CC-401 on gene expression on day 14 of
anti-GBM disease. Anti-GBM disease was induced in rats that
received CC-401, vehicle (Veh), or no treatment (no Tx), throughout a
14-day study. RNA was extracted from whole kidney samples and
analyzed by real-time reverse transcription-polymerase chain reaction
for (a) TNF-a, (b) iNOS, (c) MCP-1, and (d) transforming growth factor-
b1, mRNA levels relative to 18S rRNA.
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A striking finding in this study was that JNK inhibition
prevented tubulointerstitial infiltration of macrophages and
T cells despite prominent glomerular macrophage accumula-
tion on day 14 of anti-GBM disease. Time-course studies
have established that glomerular injury precedes tubulointer-
stitial damage in the progression of accelerated rat anti-GBM
glomerulonephritis.27 Given that the deposition of sheep Ig is
limited to the GBM, it is thought that indirect activation of
tubular cells by glomerular cytokine secretion and/or
increased protein levels in the urinary space, causes
upregulation of chemokines and adhesion molecules by
tubular cells leading to the recruitment and activation of
macrophages and T cells.43 The ability of CC-401 treatment
to prevent tubulointerstitial leukocyte infiltration is most
likely due to suppression of tubular cell activation as a result
of inhibition of glomerular inflammation and cytokine
production (via inhibition of macrophage activation as
discussed above) and the reduction in proteinuria. Indeed,
this postulate is supported by the finding that JNK blockade
prevented upregulation of renal MCP-1 mRNA levels on day
14 when MCP-1 is predominantly expressed by tubules.41,44
It has previously been shown that tubular MCP-1 is essential
for tubulointerstitial macrophage infiltration in anti-GBM
disease.41,44
T cells play a critical role in directing immune-mediated
renal injury in progressive anti-GBM disease.45,46 However,
CC-401 did not appear to affect the T-cell response in anti-
GBM disease given the lack of effect of JNK blockade on
acute glomerular T-cell recruitment and in the skin delayed-
type hypersensitivity response. It is presumed that the
reduction in interstitial T cells on day 14 of anti-GBM
disease seen with CC-401 treatment simply reflects the lack of
tubulointerstitial damage resulting from reduced proteinuria
and cytokine production. Studies in gene knockout mice
have shown that JNK1 is important in the primary immune
response in which naı¨ve T cells differentiate into T-helper
type 1 cells.8,9 In this study, JNK blockade with CC-401 did
not change the relative proportions of the IgG isotypes in the
rat response to sheep Ig, suggesting that the T-helper type 1
response was unaltered. One reason for the lack of effect of
JNK blockade upon the T-cell response may be that drug
treatment did not begin until the time of the secondary
antigen challenge when the primary immune response was
already established. Thus, this study argues that JNK
signaling is not required for the secondary T-cell response,
an issue not previously examined in renal or non-renal
disease.
JNK blockade caused an increase in serum levels of rat IgG
against the immunizing antigen, suggesting that JNK
signaling may modulate the humoral immune response.
There are two possible mechanisms by which this may
operate. First, it is known from in vitro studies that JNK
activation can cause plasma-cell apoptosis.47,48 Thus, inhibit-
ing B-cell and plasma-cell apoptosis by JNK blockade could
potentially increase the production of rat anti-sheep IgG in
the immune response. Second, the reduction in the degree of
proteinuria seen with CC-401 treatment may contribute to
protection against urinary loss of serum Igs. This potential
mechanism is supported by the significant correlation
between serum levels of rat anti-sheep IgG and the degree
of proteinuria on day 14 of anti-GBM disease, which is also
apparent in the CC-401-treated group when analyzed
separately. However, further studies are required to define
precisely the mechanisms responsible for increased serum rat
anti-sheep IgG titers in the CC-401-treated animals.
In summary, this study has demonstrated a pathological
role for JNK signaling in acute and progressive rat anti-GBM
glomerulonephritis. These protective effects were associated
with inhibition of macrophage activation, whereas the
neutrophil influx and the acquired immune response did
not appear to be affected. JNK inhibitors may be a novel
therapeutic approach for the treatment of human glomerulo-
nephritis.
MATERIALS AND METHODS
Antibodies
The following rabbit antibodies against: phospho-JNK (Tyr183/
Tyr185); c-Jun; phospho-c-Jun (Ser63); phospho-p44/42 mitogen-
activated protein kinase (Thr202/Tyr204); and phospho-p38
(Thr180/Tyr182) were obtained from Cell Signaling (San Deigo,
CA). Other antibodies used were: rabbit anti-a1 tubulin (Abcam,
Cambridge, MA), mouse anti-CD68-recognizing rat macrophages
(ED1), and mouse anti-rat T-cell receptor (R73) (Serotec, Oxford
UK); RP-1-recognizing rat neutrophils (Becton Dickinson, San
Diego, CA); mouse anti-vimentin (Dako, Glostrup, Denmark); and
fluorescein isothiocyanate-conjugated rabbit antibodies to rabbit
IgG, rat IgG, and rat C3 (Sigma-Aldrich, Castle Hill, NSW,
Australia). Secondary antibodies included: biotinylated goat anti-
rabbit IgG, biotinylated rabbit anti-goat IgG, biotinylated goat
antibodies reactive with mouse IgG1, IgG2a, and IgG2b isotypes and
total IgG, and streptavidin-conjugated horseradish peroxidase (all
from Zymed-Invitrogen, Carlsbad, CA). Horseradish peroxidase-
conjugated goat anti-mouse IgG, mouse peroxidase-conjugated
anti-peroxidase complexes, alkaline phosphatase-conjugated goat
anti-mouse IgG, and mouse alkaline phosphatase-conjugated anti-
alkaline phosphatase complexes (all from Dako).
Animals
Sprague–Dawley rats were obtained from Monash Animal Services,
Clayton, Australia. All animal experimentation was approved by the
Monash Medical Centre Animal Ethics Committee.
Western blot analysis
Glomeruli were isolated by differential sieving and then lysed in
SDS-PAGE sample buffer, boiled, centrifuged, and the supernatant
recovered. Samples were separated by SDS-PAGE, electroblotted
onto nitrocellulose membranes, incubated with Blocking Buffer
(LiCor Biosciences, Lincoln, NE) for 1 h, and then incubated with
primary antibody overnight at 41C. Blots then were washed and
incubated with Alexa Fluor 680 goat anti-rabbit IgG (Molecular
Probes Inc., Eugene, OR) for 30 min and analyzed by the Odyssey
infrared imaging system (LiCor Biosciences). Blots were reprobed
for tubulin as a loading control. Results were quantified using the
Gel-Pro Analyzer program (Media Cybernetics, Silver Springs, MD,
USA).
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CC-401
The specific JNK inhibitor CC-401, a newer generation inhibitor
than SP600125, was synthesized by Celgene (San Diego, CA) and has
been characterized previously.19,25 It is a potent inhibitor of all three
forms of JNK (Ki of 25–50 nM), and has at least 40-fold selectivity for
JNK compared with other related kinases, including: p38, ERK,
IKK2, PKC, Lck, and ZAP70. CC-401 acts to inhibit JNK signaling
by competitive binding to the adenosine triphosphate-binding site
in the active, phosphorylated, form of JNK, resulting in inhibition of
the phosphorylation of JNK targets, such as the amino-terminal
activation domain of the transcription factor, c-Jun. In cell-based
assays, 1–5 mmol/l CC-401 provides specific JNK inhibition. CC-401
is prepared in a sodium citrate vehicle and administered to rats by
twice daily gavage. Serum levels of CC-401 were analyzed by high-
pressure liquid chromatograph.
CC-401 treatment of anti-GBM glomerulonephritis
Passive accelerated anti-GBM disease was induced in male
Sprague–Dawley rats (130–160 g) as described previously.26 Briefly,
rats were immunized by subcutaneous injection of 5 mg of sheep
IgG in Freunds complete adjuvant followed 5 days later (termed day
0) by a tail vein injection of 5 ml/kg sheep anti-rat GBM serum. In
all of the studies, CC-401 or vehicle treatment was begun 2 h before
anti-GBM serum administration and continued twice daily there-
after until animals were killed. Three separate studies were
performed in which animals were killed at 3 h (n¼ 6 or 7), 24 h
(n¼ 6 or 7), or 14 days (n¼ 14 for CC-401, n¼ 11 for vehicle
treated and n¼ 10 for no treatment) after anti-GBM serum
administration. Animals were housed in metabolic cages for 22 h
to collect urine on days 1, 7, and 14. Blood was collected at the time
of death. In the day 14 study, a skin delayed-type hypersensitivity
response was examined. Twenty-four hours before being killed, each
animal was given three separate intradermal injections of 0.1 ml each
of sheep IgG (1 mg/ml), rabbit IgG (1 mg/ml), and normal saline.
Skin thickness at the site of injection was measured using engineer’s
calipers at the time of killing by an investigator blinded to the
treatment regimen. Analysis of serum creatinine and urinary protein
were performed by the Department of Biochemistry, Monash
Medical Centre.
Renal histology
Paraffin sections (2 mm) of methylcarn-fixed tissue were stained
using PAS and hematoxylin. In the 14-day anti-GBM disease model,
glomerular lesions were analyzed under high power ( 400) on
PAS-stained sections. Each glomerulus within the section was
scored. Glomerular lesions were defined by hyalinosis, focal and
segmental adhesions, fibrinoid necrosis, and glomerular atrophy.
Grading was based on the proportion of the glomerulus that had
these lesions: 0, no damage; 1þo10%; 2þ 10–25%; 3þ 25–50%;
4þ450%. Tubulointerstitial lesions were assessed on the basis of
tubular dilatation, atrophy, necrosis, protein casts, and mononuclear
cell infiltration. The percentage of the cortex involved in
tubulointerstitial lesions was scored as: 0, no damage; 1þo10%;
2þ 10–25%; 3þ 25–50%; 4þ450%. Scoring was performed on
blinded slides.
Immunohistochemistry
Immunoperoxidase staining for p-JNK, c-Jun, p-c-Jun Ser63,
vimentin, and ED1þmacrophages was performed on 4 mm sections
of formalin-fixed tissue using antigen retrieval (microwave oven
heating in 0.1 M sodium citrate pH6.0 for 10 min) followed by a
three-layer avidin-biotin peroxidase complex staining method.49
Immunoperoxidase staining for R73þT cells and RP1þ neutro-
phils used frozen sections of tissue fixed in 2% paraformaldehyde-
lysine-periodate with a three-layer peroxidase anti-peroxidase
method. Two color immunostaining used formalin sections in
which p-c-Jun Ser63þ cells were stained using the avidin-biotin
peroxidase complex peroxidase-based method, followed by staining
for ED1þmacrophages using an alkaline phosphatase-conjugated
anti-alkaline phosphatase method with Fast-Blue substrate devel-
opment as described previously.50
Quantification of immunostaining
Glomerular accumulation of RP1þ neutrophils was analyzed under
high power ( 400) in 50 glomeruli per animal by image analysis
using Image-Pro software (Media Cybernetics) and expressed as a
percentage of the glomerular tuft area. Tubular vimentin immuno-
staining was quantified by scoring tubules in  250 fields.
A positive tubule cross-section was defined as having two or more
stained cells. All tubules in the cortex were assessed for each animal.
The number of glomerular ED1þmacrophages and R73þT cells
were counted under high power ( 400) in 50 glomeruli per
animals. Interstitial ED1þ and R73þ cells were counted in the
entire cortex using high power fields ( 400). All scoring was
performed on coded slides.
Real-time reverse transcription-polymerase chain reaction
Total RNA was extracted from whole kidney samples using the
RiboPure reagent (Ambion Inc., Austin, TX) and reverse transcribed
using the Superscript First-Strand Synthesis kit (Invitrogen,
Carlsbad, CA) with random primers. Real-time polymerase chain
reaction was performed on Rotor-Gene 3000 system (Corbett
Research, Sydney, Australia) with thermal cycling conditions of 371C
for 10 min, 951C for 5 min, followed by 50 cycles of 951C for 15 s,
601C for 20 s, and 681C for 20 s. The primer pairs and FAM-labelled
MGB probes used were: TNF-a (forward: CTT ATC TAC TCC CAG
GTT CTC T; reverse: TCT CCT GGT ATG AAA TGG CAA A; and
probe: TCA CCC ACA CCG TCA G), iNOS (forward: TTC AGA
GTC AAA TCC TAC CAA G; reverse: TGT GTT GTT GGG CTG
GGA ATA; and probe: GAA AGA GGA AAA GGA CA), MCP-1
(forward: TGA CCC ATA AAT CTG AAG CTA A; reverse: GGC ATC
ACA TTC CAA ATC ACA C; and probe: ACA ACC ACC TCA AGC
AC), and transforming growth factor-b1 (forward: GGA CAC ACA
GTA CAG CAA; reverse: GAC CCA CGT AGT AGA CGA T; and
probe: ACA ACC AAC ACA ACC C). The relative amount of mRNA
was calculated using comparative Ct (DDCt) method. All specific
amplicons were normalized against 18S rRNA, which was amplified
in the same reaction as an internal control using commercial assay
reagents (Applied Biosystems, Scoresby, Vic., Australia).
Assessment of the humoral response in the anti-GBM disease
model
Kidney deposition of sheep IgG, rat IgG, and complement C3 was
detected on snap-frozen cryostat sections by direct immuno-
fluorescence staining with fluorescein isothiocyanate-conjugated
antibodies. Semiquantification of the immunofluorescence staining
was performed using an antibody titration method on blinded slides
as described previously.51 Circulating levels of rat IgG subtypes
reactive with sheep IgG were quantified by a sandwich enzyme-
linked immunosorbent assay, as described previously.51
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Statistical analysis
Data are presented as mean71 s.d. Analysis between groups of
animals was performed by parametric analysis of variance using
Tukey’s post-test for multiple comparisons. Non-parametric data
were analyzed by the Kruskal–Wallis analysis of variance by ranks
using Dunn’s post-test for multiple comparisons. Correlation
analysis used the Pearson single correlation coefficient (GraphPad
4.0 Software, San Diego, CA).
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